A Third Raise on a Cheaper Stock: The $20.50 Floor and a 2027 Pointer Above the Street Reopen the Discount We Waited For

Results vs. Consensus

We downgraded UnitedHealth to Hold in July on valuation, not on fundamentals. The stock had round-tripped from ~16x at the January washout to ~21x a guide that leaned on favorable development, and we said we would come back on a pullback that reopened a discount. Three months later the pullback has happened and the fundamentals have kept improving, so this recap has two jobs: test the quality of a third straight beat-and-raise, and decide whether the cheaper entry is worth taking.

Adjusted EPS of $4.69 beat a consensus of roughly $4.12 to $4.14 by about $0.55 and rose 61% from $2.92 a year ago. GAAP EPS was $4.56 against $2.59. Revenue of $112.7 billion was down 0.4% year-over-year but about 1.2% above the ~$111.4 billion the Street expected, with UnitedHealthcare revenue of $86.3 billion running well ahead of its segment estimate. Earnings from operations rose 52% to $6.6 billion and the operating margin widened to 5.8% from 3.8%. The consolidated medical care ratio was 88.4%, 150bp better than a year ago and better than the Street had modeled, but it again carried a sizable reserve tailwind: $610 million of net favorable development, all of it tied to 2026 dates of service.

Q3 2026 Scorecard

Year-Over-Year Comparison (Q3)

Quarter-Over-Quarter Comparison

Quality of Beat

• Revenue: Down 0.4% to $112.7 billion, and up only 0.6% through nine months, because premiums fell 2.1% as UnitedHealthcare kept shedding members it priced out of the book. The growth came from products (+7.5%) and services (+5.0%), the Optum side of the ledger, which partly offset the smaller insured base. The beat against consensus was driven by UnitedHealthcare, where premium revenue held up better than the membership declines implied. This is still a top line traded for margin on purpose, and the market has started to ask when it turns.
• Margins: The operating margin widened 200bp to 5.8% on two levers at once: a 150bp lower medical care ratio and a 70bp lower operating cost ratio. The cost-ratio improvement is the cleaner of the two, since the release attributes it to realized operating efficiencies net of stepped-up investment. The MCR improvement is real but partly reserve-assisted: adding back the $610 million of development puts the underlying ratio near 89.1%, still roughly 80bp better than the year-ago quarter on the same basis.
• EPS: The bridge from $4.56 GAAP to $4.69 adjusted was small: $0.41 of intangible amortization, offset by a $0.16 net gain on portfolio divestitures and an $0.08 restructuring benefit (mostly a release of loss-contract reserves), and a $0.04 tax effect. The add-backs totaled $0.41 and the deductions $0.28, so the adjusted figure sits only $0.13 above GAAP. The headline beat is operational in origin but reserve-assisted in size, and it came despite a tax rate nearly four points above the full-year guide, which is a quiet positive.

Segment Performance

Both engines grew earnings sharply year-over-year off a depressed Q3 2025 base, and both stepped down sequentially in the seasonal pattern management laid out in July. UnitedHealthcare's operating margin of 3.3% compares with 2.1% a year ago and 4.6% in Q2; the first-half weighting of insurance earnings is doing exactly what was guided. Optum's margin rose 200bp year-over-year to 5.6%, led by Optum Health's swing from breakeven to $735 million. As in prior quarters, the Optum Health and Optum Insight comparatives are recast for the January 1, 2026 move of Optum Financial into Optum Insight.

Segment Results: Q3 2026

Consolidated and Optum totals include intersegment eliminations, so the segment rows do not sum to the totals.

UnitedHealthcare Revenue by Business: Q3 2026

UnitedHealthcare: Medicare Recovers, Commercial Plateaus

UnitedHealthcare revenue slipped 0.8% to $86.3 billion, but earnings from operations rose 57% to $2.8 billion and the operating margin widened to 3.3% from 2.1%. On an adjusted basis, which strips a $141 million net portfolio gain, earnings were $2.7 billion at a 3.1% margin. The segment's earnings are front-loaded by design, so the 130bp sequential step-down from Q2's 4.6% is the seasonal pattern, not a deterioration. The more useful read is the mix. Medicare and Retirement revenue fell 2.2% to $42.4 billion on deliberate membership exits, yet that is the business producing the margin recovery: management now expects Medicare margins near the top end of its 2% to 4% range for 2026, up from "above 3%" a quarter ago. Medicare Advantage membership rose 40,000 sequentially to 7.6 million, a second straight quarterly gain and the largest of the year, after a contraction of 935,000 since year-end on the company's broader count. Community and State revenue was essentially flat at $23.7 billion. Employer and Individual revenue grew 1.7% to $20.2 billion even as people served fell 165,000.

"UnitedHealthcare is seeing positive momentum across our Medicare and Medicaid businesses. While our commercial business continues to adjust to a challenging but steadily stabilizing environment." — Tim Noel, UnitedHealthcare CEO

Commercial is the book to watch. Trend continues to exceed the 11% the company priced to, driven by No Surprises Act arbitration, rising clinician cost intensity and specialty drugs, and management priced 2027 on the assumption that it persists. The risk-based commercial book shrank 10% year-over-year to 7.6 million lives while fee-based lives grew to 22.2 million, which lowers the earnings at stake but also the leverage to a recovery. The commercial business also has a new chief executive, introduced on this call.

Assessment: The two-speed segment we described in July is still two-speed, but the slow engine has stopped slowing down. Medicare is ahead of plan for a second straight quarter and Medicaid is past its trough, which together cover most of the segment's earnings. Commercial has moved from accelerating trend to trend that is stabilizing at a high level, which removes the July fear that it was a widening hole, but it pushes the 7%-plus commercial margin further into the future. We now treat commercial as a multi-year drag on the out-years rather than a 2027 recovery lever.

Optum Health: A Profitable Third Quarter, and a Q4 Loss That Looks Conservative

Optum Health revenue fell 9.9% to $22.9 billion as the company exited markets where it lacked enough value-based-care density to support its clinicians. Earnings from operations were $735 million at a 3.2% margin, compared with $41 million and 0.2% a year ago. Adjusted for an $85 million portfolio gain and a $62 million restructuring benefit, earnings were $588 million at a 2.6% margin. In July management guided to a modest Optum Health profit in Q3 offset by modest losses in the fourth quarter; Q3 was more than modest. Through nine months Optum Health has earned $3.07 billion on an adjusted basis, so the July full-year guide of at least $2.215 billion adjusted would allow a fourth-quarter loss of up to about $859 million. Management did not refresh that guide, but it did say the third-quarter performance "will be durable into the fourth quarter," with Q4 burdened by normal risk seasonality and clinician-workflow and AI investments.

"Again, I think 2027 is a year where we'll see a strong pace towards that 6%-8% by 2028. That is really our focus." — Krista Nelson, Optum Health COO

The operating indicators support the durability claim: online self-scheduling up 27% year-over-year, home health visits up 10%, and behavioral-health referrals within primary care doubled with engagement above 90%. Optum Health serves about 20 million patients, roughly 4 million of them in fully accountable arrangements, and management pointed to professional capitation, shared savings and post-acute risk products as the next growth channels.

Assessment: This is the segment our thesis hinges on, and it gave the cleanest new information in the print: a 6% to 8% margin target with a date on it (2028), and a third quarter that held a ~3% margin after the first-half peak. The arithmetic of a nine-month $3.07 billion against a $2.215 billion floor means the full-year number is likely to clear its guide by a wide margin unless Q4 is far worse than "durable" implies. The level is still early: 2.6% adjusted in Q3 is less than half of the target floor.

Optum Insight: The Investment Year Still Produced a 23% Margin

Optum Insight revenue grew 2.9% to $5.5 billion and earnings from operations rose 39% to $1.3 billion, a 23.4% margin against 17.3% a year ago. Management credited payment-integrity products and AI-driven operating efficiency, while describing 2026 as "both a performance and an investment year." The AI product pipeline is the forward story: the Integrity One coding product went from two clients at the end of 2025 to 15 implemented and 24 implementing, and the unit has joined the Anthropic Partner Network alongside earlier go-to-market partnerships with Microsoft and Google, with a series of product launches promised over the next two quarters.

"2026 has been both a performance and an investment year, and 2027 will show meaningful progress, setting the foundation for accelerating growth in 2028 and beyond." — Patrick Conway, Optum CEO

Assessment: Insight keeps posting margins well above its history while management says it is investing, which suggests the AI efficiency is real inside the business before it is a product outside it. Revenue growth of 3% is modest and the company is still rationalizing legacy contracts, so this remains margin ballast and optionality rather than a growth engine until 2028. We would not extrapolate the 23% margin into a growth story yet.

Optum Rx: The Steady Grower Crosses a Line

Optum Rx revenue was $39.9 billion, up 0.6%, and earnings from operations rose 10.9% to $1.7 billion at a 4.3% margin, helped by biosimilar adoption and operating improvement. Adjusted scripts were 393 million, down 5.1% year-over-year on lower UnitedHealthcare and client membership but up 1.6% sequentially. For the first time, more than half of Optum Rx membership is external to UnitedHealthcare. Specialty volumes grew 2.6% in a quarter when overall volumes fell 5%, and retention stayed in the high 90s through the 2027 selling season.

"For the first time, over 50% of Optum Rx membership is external, non-UHC membership." — Patrick Conway, Optum CEO

Assessment: The external-majority milestone matters more than the quarter. It shows the transparent, fee-based PBM model is winning business on its own merits rather than living off the captive insurer, which is the best answer to the regulatory argument that vertical integration is the source of the PBM's earnings. The open question is the fourth quarter: nine-month earnings of $4.4 billion leave $1.85 billion to reach the July guide of at least $6.25 billion, which would be its best quarter of 2026, and the company did not reaffirm that guide.

Key Membership & Performance Metrics

Key Topics & Management Commentary

Overall Management Tone: Management was confident and unusually forward-leaning, volunteering a 2027 earnings floor ahead of its formal outlook, due before year-end, and saying the Street's 2027 number may be too low. The posture was less expansive on the current year: the full guidance table of July gave way to a single EPS floor, and several segment questions were deferred to a year-end investor update. The tone was the most assured of the turnaround so far on direction, and slightly more guarded than in July on detail.

1. The Third Raise, and a Return to a Floor

Full-year adjusted EPS guidance moved to "at least $20.50" from the $19.50 to $20.00 range set in July, which was itself a raise from the greater-than-$18.25 floor of April and the greater-than-$17.75 floor of January. GAAP EPS guidance moved to at least $19.50 from $18.45 to $18.95. The raise is $0.75 at the July midpoint and $0.50 above the top of the old range. With nine-month adjusted EPS at $18.30, the new floor requires only $2.20 in the fourth quarter, against $2.11 in the fourth quarter of 2025, a quarter in which Optum Health lost money even on an adjusted basis.

"Turning to the full year, our updated 2026 adjusted EPS guidance of at least $20.50 reflects performance through the third quarter, balanced by expected investments in the final months of the year." — Wayne DeVeydt, CFO

The switch from a range back to "at least" language with one quarter left is the subtle part. In July the move from a floor to a range read as a visibility signal; going back to a floor in October reads as cushion. A $2.20 fourth quarter would be barely above a year-ago quarter that was close to the bottom of the cycle, and management named fourth-quarter investments in Stars, clinician workflows, AI and policy reforms as the reason for the restraint.

Assessment: The pattern of 2026 is intact: every guide this finance team has set has been beaten and raised, and this one is built the same way. The pre-print Street sat near $19.86, so the raise passes through the third-quarter beat and adds a little more. We think the floor is conservative and model $20.55 to $20.70.

2. The 2027 Pointer: A Floor Above the Street

The most consequential sentence of the call was about next year. Management formally reserved 2027 guidance for an investor update before year-end, but the CFO said current 2027 consensus may understate the opportunity and offered the low end of the long-term 13% to 16% growth range as the more reasonable starting point. Applied to the $20.50 floor, that is at least about $23.17, against a pre-print Street near $22.6 to $22.8.

"We view our 2026 adjusted EPS guidance of at least $20.50 as a solid run rate on which to grow. We would offer that current analyst consensus for 2027 may understate the opportunity ahead, and we see the lower end of our long-term 13%-16% growth rate as a more reasonable starting point." — Wayne DeVeydt, CFO

Management framed 2027 as a balance. The tailwinds it listed were enterprise-level performance progress, share repurchases, value-based-care improvement, and AI-driven productivity. The headwinds were accelerated investment in policy reforms and modernization, particularly at UnitedHealthcare and Optum Insight, plus continued respect for medical trend in a pressured funding environment. The CEO noted that the company had already offered more forward-looking color than it usually would at this stage.

Assessment: This is the piece of the print that changes our valuation math. A management team that has beaten every 2026 number is now putting a public floor under 2027 that sits about 2% above the Street, before the year has been fully priced. The caveat is the base: "solid run rate" includes a year of favorable reserve development, so growing 13% off $20.50 is a slightly higher bar than it looks. We still take the pointer at close to face value and model $23.2 to $23.6.

3. An 88.4% MCR and $610 Million of In-Year Development

The medical care ratio of 88.4% improved 150bp year-over-year and stepped up 170bp from Q2's seasonal low, which is the expected shape of the year. The release attributes the improvement to medical cost management, benefit design changes and pricing discipline, plus care-delivery changes in value-based care. The reserve development was smaller than in Q2 ($610 million versus $860 million) and, unlike Q2, the company tied all of it to 2026 dates of service. Days claims payable held at 47.0, unchanged from Q2 and up 0.8 days from a year ago, so the reserve base is not being visibly run down to produce the number.

"The quality of earnings is strong and durable as we head into 2027. At UnitedHealthcare, performance continued to reflect pricing discipline, fundamental medical cost management, and care delivery enhancements." — Wayne DeVeydt, CFO

Adding back the development puts the underlying ratio near 89.1%, about 80bp better than the year-ago quarter on the same basis. Through nine months the consolidated ratio is 86.3%, well below the 88.1% full-year guide set in July, which the company did not update. Meeting even the low end of that guide would require a fourth-quarter ratio of roughly 92.5% or more, at or above the 92.4% of the fourth quarter of 2025, the peak of last year's cost crisis. We read the guide as stale rather than as a warning.

Assessment: The repricing is in the numbers and the reserves look conservative, both positives. The bear point is fair but narrower than it sounds: in-year development flatters the quarter's share of the year, not the year. We would worry if days claims payable started to fall while development stayed this large; that is not happening.

4. Medicare: Margins Near the Top of the Range, and a Disciplined 2027 Bid

Medicare was the strongest business again. Management now expects 2026 Medicare Advantage margins near the top of its 2% to 4% range, from "above 3%" in July, and described trend as bending in a more stable direction while explicitly not assuming any return to historical patterns. For 2027 the company kept the same discipline it applied for 2026: continued footprint refinements in residual PPO products, a focus on dual-eligible and chronic special-needs plans and high-value HMOs, and a broader overall footprint, with more than 94% of Medicare-eligible Americans able to buy a UnitedHealthcare plan and about 90% having access to a $0-premium option.

"Care intensity remains elevated relative to historical norms, even as we continue to see signs that trends are bending in a more stable direction than what we have recently experienced. We remain respectful of trends, and are not assuming any deceleration to historical patterns or to ongoing clinician pricing pressure." — Tim Noel, UnitedHealthcare CEO

Membership has turned. After falling hard in January, Medicare Advantage lives rose for a second straight quarter, to 7.6 million. Management declined to give 2027 membership guidance ahead of the annual enrollment period, which began two days after the call, but said the company is better positioned to grow in its target segments than in recent years.

Assessment: The Medicare margin is now running ahead of plan two quarters in a row, which is the cleanest evidence that the 2026 repricing worked. The 2027 bid continues the margin-first posture, so we do not expect much Medicare Advantage growth next year; the value is in the margin holding near the top of the range while the trend environment stays elevated.

5. Star Ratings: In Line With Expectations, but Lower

The 2027 Star ratings, released the week before the print, put at least 69% of UnitedHealthcare's Medicare Advantage members in plans rated four stars or higher. The release called that in line with expectations and pointed to improvement in 11 of 12 HEDIS measures and all four pharmacy measures. It is still a step down from roughly four-fifths in last year's ratings, and these ratings drive the quality bonus payments of 2028. Management linked the decline to the 2026 benefit repositioning and said it expects to approach 75% of members in four-star-plus plans, against an industry average near 70%, as it moves through 2027 and into 2028.

"Our initial Star Ratings for payment year 2028 reflect our investment in quality, member experience, and operating execution. As we move through 2027 and into 2028, we expect to approach 75% of total members in four-plus Star plans compared to the industry average of 70%." — Tim Noel, UnitedHealthcare CEO

Assessment: This is a known, sized headwind for 2028 revenue rather than a surprise, and the company is spending against it now. It matters for the out-year algorithm: fewer members in bonus-eligible plans is a drag the 13% to 16% growth target has to absorb in 2028. We treat it as a watch item inside the funding risk, not a thesis-breaker.

6. Commercial: Stabilizing at a Level That Still Hurts

In July commercial trend was "modestly above 11%" and rising. In October it is still above 11% but no longer rising, and management described it repeatedly as stabilizing. The causes are unchanged: abuse of the No Surprises Act arbitration process, rising clinician cost intensity, and specialty drugs. The company priced 2027 assuming the high trend persists, and it said the elevated trend will again stretch out the timeline for reaching its long-term commercial margin targets, with more detail promised at the year-end update.

"Of particular concern is the ongoing abuse of the No Surprises Act dispute process by a relatively small number of clinician groups and third-party organizations. Arbitration awards can approach nearly 6% of total medical spend in some regions, translating to billions of dollars in excess costs for consumers, employers, and the health system." — Tim Noel, UnitedHealthcare CEO

The commercial business has a new chief executive, who reported strong national-accounts persistency and retention heading into 2027 and good momentum in mid-market and the Surest product. In response to a policy question, management said arbitration awards in some instances reach 10 to 11 times what Medicare would pay.

Assessment: "Stabilizing" is the best word the July bear case could have hoped to hear, and it removes the risk of a widening hole in 2027. It is not recovery. The arbitration cost is external, regionally concentrated, and dependent on regulatory change the company does not control, so we assume commercial margins stay depressed through 2027 and treat any recovery as upside.

7. Medicaid: The Trough Is Shallower Than Guided

Medicaid improved in the quarter. Management now expects 2026 core Medicaid margins moderately better than negative 1%, compared with the negative 1% to negative 1.7% range given in July, citing complex-care cost management, network curation, member engagement and fraud, waste and abuse work. Trend remains elevated in behavioral health, specialty pharmacy, home and community-based services, and inpatient care, but is moderating slightly. The aim is to reach target margins by the end of 2028, even as federal Medicaid reforms phase in from 2027 through 2030.

"Based on our current outlook, we continue to view 2026 as a trough year for core Medicaid margins, which we now expect to be moderately better than negative 1%." — Tim Noel, UnitedHealthcare CEO

Assessment: A trough that comes in better than guided is the right direction, and state rate actions plus the company's own cost work should keep it moving. Medicaid is still a loss-making book in 2026 and a two-year repair, so it is a small positive to the 2027 algorithm rather than a driver.

8. The Affordability Agenda: Prior-Authorization Cuts and the Foundation

The prepared remarks spent unusual time on reputation and access. The company is on track to complete all previously announced prior-authorization reforms by year-end, cutting total prior authorizations by 30% and those for people under 18 by two-thirds. It has committed $1 billion to the refreshed United Health Foundation, is accelerating payments to 1,500 rural hospitals, and is rebating 2026 profits from individual ACA coverage to about 1 million members. The CEO described the effort as listening to customers, clinicians and policymakers "with humility" and said more will follow.

"Collectively, these initiatives will reduce total prior authorizations by 30%, including a reduction of two-thirds in prior authorizations for people under the age 18. These efforts are only the beginning. More will follow." — Stephen Hemsley, Chairman & CEO

Assessment: These are costs today and goodwill tomorrow. They lower friction with clinicians and regulators at a time when the company's largest unresolved risk is regulatory, and they are part of the investment spending that makes the fourth-quarter floor look conservative. We see them as necessary rather than optional, and as a modest offset to political risk rather than a source of earnings.

9. AI and the Operating Cost Ratio

The operating cost ratio of 12.8% was 70bp better than a year ago and roughly flat with Q2's 12.7%. Management gave concrete operating metrics for the AI program: chart summarization now used by more than 40% of employed clinicians, cutting chart-review time by 33%; appeal cycle times down 26%; AI-assisted plan recommendations for the Medicare enrollment period; and agentic claims adjudication delivered to an outside Medicaid plan through the Optum AI consulting practice.

"We have expanded AI-enabled chart summarization to more than 40% of our employed clinicians, reducing chart review time by 33%. AI-enabled information gathering and research have shortened appeal cycle times by 26%, improving both member and clinician experience, and we expect this to accelerate in 2027." — Stephen Hemsley, Chairman & CEO

Assessment: For the second straight quarter the cost ratio is behaving, which is the mechanical evidence that the AI spending is paying for itself inside the business. Management listed further AI gains as a 2027 tailwind but did not size them, and we continue to treat AI as the reason the cost line is contained rather than a separately underwritten source of upside.

10. Capital Deployment: Buyback Complete, Cash Flow Ahead of Guide

The company has repurchased $5.0 billion of stock through September, meeting the "at least $5 billion" target set in July with a quarter to spare, and paid $6.2 billion of dividends with more than $8 billion expected for the year. Operating cash flow was $5.1 billion in the quarter (1.2x net income) and $25.1 billion through nine months, already above the ~$24 billion full-year figure guided in July. Debt-to-capital edged up to 41.7% from 41.2% in Q2, though total debt has fallen to $74.3 billion from $78.4 billion at year-end, and the company says it remains on track to approach 40% by year-end.

"Our debt-to-cap ratio was 41.7% at the close of the quarter, and we remain on track to approach 40% by year-end. We repurchased $5 billion of UNH stock through the third quarter. We have paid $6.2 billion in dividends year to date and expect to exceed $8 billion by year-end." — Wayne DeVeydt, CFO

Assessment: Capital return is delivered rather than promised. The small rise in leverage is worth watching but is not a concern with nine-month cash flow running at 1.5x net income. With the buyback target met, the next signal is the 2027 capital plan at the year-end update; share repurchases are on management's list of 2027 tailwinds.

11. DOJ and Regulation: Still Silent, Now on Offense on Policy

For the sixth consecutive quarter the call offered no comment on the Department of Justice matters, which remain listed among the risk factors in the release. Management was more vocal on policy than in prior quarters, arguing for reform of the No Surprises Act arbitration process and describing an active dialogue with CMS on Medicare Advantage modernization, with an emphasis on program stability.

"We are supportive of modernization. We are supportive of reform that advances the program and ensures sustainability of the program." — Bobby Hunter, UnitedHealthcare Medicare & Retirement

Assessment: The DOJ tail is unquantified, unaddressed and the single largest risk we cannot size, exactly as in July. What has changed is the price: at ~21x it was a reason not to own the stock; at ~19.6x the new floor and ~17.3x the 2027 pointer, part of it is now in the multiple. It remains the main reason our conviction is 6 rather than higher.

Guidance & Outlook

The company raised its EPS outlook but published far less than in July. The July release carried a full table of segment operating earnings, medical care ratio, tax rate, cash flow and buyback guidance; the October release carried only the EPS and net-earnings outlook. The table below shows what moved and what was left at its July level.

Several July segment guides are now plainly stale. UnitedHealthcare has already earned more than its full-year floor, Optum Health has earned roughly $860 million more than its adjusted floor, and cash flow has passed its full-year figure with a quarter to go. Others still need a big fourth quarter: Optum Rx must earn about $1.85 billion, which would be its best quarter of the year.

Implied Q4: Nine-month adjusted EPS is $18.30 ($7.23 in Q1, $6.38 in Q2, $4.69 in Q3), so the floor implies at least $2.20 in Q4, against $2.11 a year ago. GAAP implies at least $2.00, against $0.01 a year ago, when the restructuring charge landed. In July the guide implied a second half of roughly $5.90 to $6.40; the new floor implies at least $6.89, because the third quarter alone delivered $4.69. Because the reserve release relates to earlier 2026 claims, it added to Q3 without borrowing from Q4, so the low floor reflects planned investment and normal seasonality rather than earnings already spent. That leaves room to beat.

Street at: Before the print, consensus sat near $19.86 for 2026 and $22.6 to $22.8 for 2027. The Street's own math implied a Q4 near $2.11 ($19.86 less $13.61 for H1 less the $4.14 Q3 estimate); the new floor of $2.20 is $0.09 above that. Post-print estimate revisions moved toward management's 2027 pointer, and price-target changes were mixed, with cuts driven by the lower share price rather than by the outlook.

Guidance style: Conservative and less detailed. The finance team has beaten every guide it has set in 2026, and this one has the same construction: a floor that needs only a flat fourth quarter on a year-ago trough. The reduced disclosure is a mild negative for transparency but probably reflects a deliberate choice to reset everything at the year-end outlook rather than refresh a table that the year has already overtaken.

Analyst Q&A Highlights

Where Medicare Advantage Margins Land in 2026

The opening question asked whether Medicaid had reached breakeven and where Medicare Advantage margins stand. Management raised its Medicare margin view to near the top of the 2% to 4% range and credited the year's recovery actions on trend, cost management and product design, adding that the cushion allows investment in quality and modernization now.

Q: "Are you actually back to kind of break even given your improvement there? Maybe you can also let us know where your MA margins are at this point for 2026."
— Justin Lake, Wolfe Research

A: "Given where we've paced through 2026, we do now expect to be near the top end of the 2%-4% range. I would attribute a lot of that to some of the great recovery actions that the team has executed on here throughout the year."
— Bobby Hunter, UnitedHealthcare Medicare & Retirement

Assessment: The clearest single upgrade on the call. Medicare is the largest earnings pool in UnitedHealthcare, and moving its margin view from "above 3%" to near the top of the 2% to 4% range in one quarter is a material improvement in the 2026 base the company will grow from.

How the Company Is Approaching Growth in 2027

A question on growth posture drew a deliberate non-answer on numbers and a clear answer on intent. Management will give membership guidance later in the year, but said it expanded its overall footprint despite exiting some residual PPO products, and is targeting special-needs plans and high-value HMOs. The new commercial chief executive described strong national-accounts retention and a solid selling season.

Q: "Could you talk a little bit about how you are approaching growth in 2027, in particular in Medicare Advantage as you are approaching the top end of the range, how you are looking at growth there?"
— Lance Wilkes, Bernstein

A: "Even with some of the footprint refinements, we did actually expand our overall footprint... We are particularly focused on the D-SNP offerings, the C-SNP offerings, and then some of the high-value HMO. I think we are better positioned to capture that growth in some of those key areas as we step into AEP in 2027 than we have been in recent years."
— Bobby Hunter, UnitedHealthcare Medicare & Retirement

Assessment: Growth is coming back as a talking point, but in narrow, margin-rich segments. That fits the margin-first strategy and means 2027 revenue growth will still be modest; the earnings algorithm rests on margin and buybacks more than on membership.

The Pace of the Commercial Margin Recovery

An analyst noted that the risk-based commercial book appears to be running below a 5% margin against a historical high-single-digit target and asked how fast it recovers. Management confirmed stabilization at high levels, said 2027 was priced for persistent trend, and conceded the long-term margin targets will take longer to reach, deferring specifics to the year-end update.

Q: "I think the risk portion, you guys have indicated that maybe that is operating at a below 5% margin. Part of that is the IDR issues that you have highlighted... I wonder your thoughts about the pacing of margin recovery there, and maybe flush out a little bit more about the stabilization you are seeing right now."
— A.J. Rice, UBS

A: "We are seeing a stabilizing of the trends... albeit at levels that are high and significantly higher than historical norms that we've seen in the commercial business. As we priced for 2027, we took the view that we would see these trends continue and persist into 2027 and priced rationally... it is going to stretch out our ability to achieve those long term objectives and margins for the commercial business."
— Tim Noel, UnitedHealthcare CEO

Assessment: The answer was candid and the pricing posture is right, but "stretch out" is the second slip in two quarters. Commercial is now a book we do not expect to contribute margin recovery before 2028 at the earliest.

Whether Trend Accelerated Through 2026

An analyst challenged the company with external data suggesting trend started the year low and accelerated, and asked whether 2027 pricing reflects the exit rate. Management rejected the premise across all three books: stabilizing in commercial, moderating in Medicaid, and better than expected in Medicare, with more real-time data now feeding pricing.

Q: "...the trend data points that we are tracking really imply that trends start off really low to start the year, but has accelerated as the year has gone on. Is this consistent with what you are seeing?... I guess how comfortable are you that you are repricing 2027 to the exit rate as far as trend goes?"
— Kevin Fischbeck, Bank of America

A: "We are not seeing the dynamics that you are talking about... In terms of trend acceleration, no, we are not seeing that. In fact, we are seeing some moderation in the government programs business and stabilization in the commercial business."
— Tim Noel, UnitedHealthcare CEO

Assessment: A direct, unhedged denial is unusual on a question this pointed, and the reported numbers support it: Medicare margins rising, Medicaid better than guided, development favorable. If the external data proves right, this is the answer that will be replayed; for now the evidence sits with management.

The Optum Health Fourth-Quarter Loss Implied by Guidance

An analyst pointed out that the unrevised Optum Health guide still implies a sharply negative fourth quarter and asked what drives the seasonality and how large the fourth-quarter investments are. Management did not size the investments but said third-quarter performance will be durable into the fourth quarter, with normal risk seasonality and clinician-workflow and AI spending as the offsets.

Q: "Optum Health's EBIT guidance still appears to imply a meaningfully negative fourth quarter. Can you walk through what's driving that sharp seasonality and help quantify 4Q investments that might be impacting that segment?"
— Andrew Mok, Barclays

A: "I mentioned the third quarter performance will be durable into the fourth quarter, but fourth quarter does reflect risk seasonality, which is normal course for this business and some additional investments that we are making for long term performance."
— Krista Nelson, Optum Health COO

Assessment: "Durable into the fourth quarter" and a guide that allows an ~$860 million fourth-quarter loss cannot both be literal. We read the guide as stale and the commentary as the better signal, which points to Optum Health finishing the year well above its July floor.

How Far Optum Health Margins Can Go

A question on where Optum Health margins land in 2027, and whether they could exceed the 6% to 8% target, prompted the CEO to cap the specificity before the year-end update. The operating leader then attached a date to the target.

Q: "...how should we think about Optum Health margins, where they land in 2027 relative to that 6%-8%? Just longer term, how you think about potential margins exceeding even that range?"
— Erin Wright, Morgan Stanley

A: "There's only so much we can say about 2027... we've already provided probably more forward-looking views than we probably have ever done on a call at this stage... [Krista Nelson:] That core performance improvement is durable and will contribute meaningfully to our outlook in 2027."
— Stephen Hemsley, Chairman & CEO, and Krista Nelson, Optum Health COO

Assessment: A "strong pace" toward 6% to 8% by 2028 is a real commitment from a segment at 2.6% adjusted in Q3. It makes Optum Health the largest single swing factor in the 2027 and 2028 algorithm, and the one most worth testing at the year-end update.

Repositioning Optum Health and Optum Insight for Growth

An analyst asked about top-line dynamics at the two Optum businesses still being repositioned. Optum Health pointed to new risk products such as post-acute risk management. Optum Insight described a multi-year program of rationalizing legacy contracts, embedding AI in existing products and launching AI-first platforms, with early client traction in coding automation.

Q: "Can you add some color on how you're thinking about your top-line dynamics for health and insight and repositioning those businesses for growth, I think, in 2028 or beyond?"
— Stephen Baxter, Wells Fargo

A: "We are continuing to rationalize existing products and contracts where they do not make sense. We are infusing AI into our existing offerings that help make them more competitive and profitable, then launching new AI first products and platforms."
— Sandeep Dadlani, Chief Digital & Technology Officer

Assessment: Both businesses are still in a shrink-to-grow phase, with revenue growth deferred to 2028. That is consistent with the earnings-not-revenue shape of the whole enterprise, and it means the bear argument about a flat top line will not be answered in 2027.

The Size and Type of Star Ratings Investments

The final question asked about investments in the Star program and the broker strategy into open enrollment. Management tied the Star pressure to the 2026 benefit changes, pointed to year-over-year improvement in nearly every clinical and pharmacy measure, and said quality spending will accelerate through the fourth quarter and into 2027.

Q: "You recently talked about making some unique investments in the Stars program... can you give us any insight into the size and maybe types of investments you are making in the Stars program?"
— Ryan Langston, TD Cowen

A: "While we knew there could be some Star pressure related to the repositioning of benefits we did for 2026 in response to the funding and policy headwinds impacting the overall industry, that is also why we made the investments we did... Think of our continued investment in 2026, Q4 and into 2027 as continuing to accelerate, not slow down, given the criticality of quality and Stars to the overall business."
— Bobby Hunter, UnitedHealthcare Medicare & Retirement

Assessment: The size was not given, which matters because quality spending is one of the named reasons the fourth-quarter floor is low. The admission that the 2026 benefit cuts cost Star ratings is the honest trade-off of the margin repair, and it will show up in 2028 revenue.

What They're NOT Saying

1. The full-year guidance table: July's release carried segment operating earnings, the MCR band, the tax rate, cash flow and the buyback; October's carried only EPS and net earnings. Several July lines are now overtaken (UnitedHealthcare, Optum Health, cash flow), one needs the segment's best quarter of the year (Optum Rx needs about $1.85 billion in Q4), and none was reaffirmed or withdrawn. Investors are left to infer which pieces still hold.
2. The DOJ exposure: For the sixth consecutive quarter there was no direct comment on the Department of Justice matters beyond the risk-factor language in the release. Magnitude, timing and possible remedies remain undisclosed, and this is still the largest risk in the franchise that we cannot size.
3. The size of the fourth-quarter investments: Investments in Star ratings, clinician workflows, AI and policy reforms are the stated reason the floor implies only $2.20 of fourth-quarter EPS, but management declined to quantify them when asked directly. The floor's conservatism rests on a number the company will not give.
4. 2027 Medicare Advantage membership and the 2028 Star-ratings cost: Membership guidance waits for the year-end update, and the revenue effect of moving from roughly four-fifths to at least 69% of members in four-star-plus plans was not sized. The headwind lands in 2028, inside the period the 13% to 16% algorithm is meant to cover.
5. How much of the "solid run rate" is reserve development: Favorable development has run near $2 billion through nine months. Management calls $20.50 a solid base to grow from but did not separate in-year development from prior-year releases or say what it assumes for development in 2027.
6. A commercial margin number and date: The commercial target was stretched again, with no current margin disclosed, no year for recovery, and no estimate of the arbitration drag beyond regional examples. Specifics were deferred "a couple of months."
7. Why leverage rose: Debt-to-capital moved up to 41.7% from 41.2% while total debt fell year-to-date, and on the call the year-end goal was phrased as being on track to "approach" 40%. The increase was not explained.
8. Long-term CEO succession: More than a year into the restart under the returning chairman and CEO, the call again said nothing about succession at the top, even as management points investors to a 2027-and-2028 compounding story.

Market Reaction

• Pre-print setup: UNH closed at $378.52 on October 12, entering the before-open print up 14.7% year-to-date (from $330.11 at the 2025 year-end) against 14.0% for the S&P 500, up 5.5% over the trailing twelve months (from $358.66) and down 0.2% over the trailing 30 days (from $379.09). The 52-week closing range was $259.02 to $436.35. Between prints the stock gave back its July gains: from the $423.38 close on the day of the Q2 print it peaked at $436.35 on July 21, then ground lower without a single 3% down day to a $365.20 low on October 1. It entered this print 10.6% below the July print-day close.
• Reaction session (October 13): The stock gapped up 5.0% to open at $397.63 and touched $399.88 (+5.6%) before reversing to a low of $372.80 (−1.5%). It closed at $377.76, down 0.2% (−$0.76), on 12.7 million shares against a 5.1 million 30-day average (2.5x). The S&P 500 was flat. Among peers, Humana fell 3.0%, Cigna 0.3% and CVS 0.2%, while Elevance rose 0.8%, Molina 2.5% and Centene 2.7%.
• Follow-through (October 14 to 16): The stock rose 4.7% to $395.62 on October 14 while the S&P 500 fell 1.1%, added 2.8% to $406.67 on October 15, and gave back 1.3% to $401.43 on October 16. That is a 6.1% gain from the pre-print close over four sessions in which the S&P 500 fell 1.9%. Cigna (+6.7%) and CVS (+5.3%) also rallied over the same span; Humana fell 4.7%.

A fade on the day, then a re-rating. The reaction session repeated July's pattern: an opening gap on a clean beat-and-raise, sold back by the close on heavy volume. In July a 7.4% gap faded to a 1.2% gain; this time a 5.0% gap faded to a 0.2% loss. The day-one sellers had specific reasons to be cautious. The beat was roughly the size of the reserve release, the guide reverted to a floor with no segment detail, people served fell again to 48.3 million, and revenue is up less than 1% for the year. That is the bear case in one print, and on the morning it won.

What happened next is the difference from July. In July the fade was the end of the story: the stock had run 43% in twelve months, sat at ~21x, and after a brief high on July 21 slid for the next ten weeks. This time the stock had already fallen 13% from its July high into the print, and once the 2027 pointer was digested, buyers came back over the following three sessions, against a falling market. The move was partly sector-wide, with Cigna and CVS also strong, so we do not credit all of it to the print. We read the sequence as the market first discounting the quality of the quarter and then pricing the higher base. Both are reasonable, and the net is a stock that still trades below where it stood when we stepped aside.

Street Perspective

Debate: Is the 2027 Pointer a Floor or a Stretch?

Bull view: The bull case argues that a finance team which has beaten and raised three times in a year does not volunteer a 2027 number it cannot hit, that the low end of 13% off a conservative $20.50 is itself conservative, and that buybacks, Optum Health's march toward 6% to 8% margins and Medicare running near the top of its range give more than enough levers to get there.

Bear view: The bear camp counts roughly $2 billion of favorable reserve development inside the 2026 base, a step-down in Star ratings that cuts 2028 bonus revenue, a commercial book whose recovery keeps slipping, and a membership base that is still shrinking, and argues that growing 13% off a flattered number with rising investment spending is harder than management is letting on.

Our take: The bulls are closer. The development this year relates mostly to 2026 claims, so it flatters the quarterly pattern more than the annual base, and most of the bear points (Stars, Optum Health maturity, commercial) bite in 2028 rather than 2027. We treat about $23.2 as a realistic floor for 2027, not a stretch.

Debate: Has the De-Rating Reopened Value, or Is the Discount Deserved?

Bull view: The optimistic view holds that the stock now trades at about 19.6x a raised 2026 floor and about 17.3x the 2027 pointer, below the franchise's historical range, while the company completes a $5 billion buyback and pays more than $8 billion of dividends. On that view, the slide from July to October was positioning, not fundamentals.

Bear view: Skeptics argue the July ~21x was the anomaly, not today's multiple. A business with a flat top line, falling membership, lower Star ratings and an unquantified DOJ exposure deserves a discount to its history, and a lower multiple on higher numbers is the market pricing those risks correctly.

Our take: We side with the bulls at today's price, though not by a wide margin. In July the market paid ~21x for a lower base; three months later it pays ~19.6x for a higher base plus a 2027 floor above consensus. Some discount for the legal tail and the Stars step-down is warranted, which is why we use ~20x rather than the 21x of July. Even with that haircut, the shares look cheap.

Debate: Is Commercial Stabilization a Floor or Just a Plateau?

Bull view: The constructive camp highlights that trend has stopped accelerating, 2027 is priced for persistence, national-accounts retention is strong, and arbitration reform is a live policy issue that could turn a structural cost into a recoverable one.

Bear view: The bear view is that trend still above 11% is a damaging level, that arbitration awards running up to about 6% of medical spend in some regions are outside management's control, that the margin target has slipped twice in two quarters, and that the risk book shrinking 10% a year limits how much any recovery can matter.

Our take: It is a plateau, and that is enough. Our thesis does not need commercial margin recovery in 2027, only that the book stops getting worse, and this quarter delivered that. Any regulatory relief on arbitration is upside we do not model.

Model Update Needed

Valuation impact: At the October 16 close of $401.43, UnitedHealth trades at ~19.6x the at-least-$20.50 2026 floor and ~17.3x the ~$23.17 2027 pointer; at the $377.76 reaction-day close those multiples were 18.4x and 16.3x. When we downgraded in July at $423.38, the stock traded at ~21.4x the $19.75 midpoint of a lower guide. Applying ~20x to our $23.2 to $23.6 2027 estimate gives a 12-month value of about $464 to $472, roughly 16% to 18% above the October 16 close, plus a 2.3% dividend yield on the $9.28 annualized payout. That is a return comfortably ahead of what we expect from the S&P 500, which is the threshold for Outperform. The math needs almost no multiple expansion: the stock trades at ~19.6x the current year today, and our value applies ~20x to the current year a year from now. It mostly needs the 2027 pointer to hold. We would return to Hold if the year-end outlook lands below the low end of the growth range, if commercial trend re-accelerates, or if the DOJ exposure is quantified at a material size. We would raise conviction if the year-end update confirms 2027 at or above $23.2 with segment detail and Optum Health on a visible path to 6% to 8% by 2028.

Thesis Scorecard Post-Earnings

We grade the quarter against the standing thesis carried since the Q2 2025 initiation and last updated at the July downgrade. The pillars are unchanged. The July note said two things would bring us back to Outperform: a pullback that reopened a discount, or evidence that commercial had stabilized and the DOJ tail had resolved benignly. The first arrived in full. The second arrived in part, with commercial stabilizing and the DOJ tail still dark.

Overall: The thesis strengthened on both axes at once, which is unusual. Operationally, Bull #1 and Bull #2 confirmed again: a third raise, a 2027 floor above the Street, Medicare running ahead of plan, Medicaid past its trough, and Optum Health holding a profitable third quarter. On valuation, Bull #3 reopened after we marked it spent in July, because the stock fell while the numbers rose. Bear #1 eased on the government side, and commercial moved from accelerating to stabilizing. What did not change is Bear #2: the DOJ tail is exactly as dark as it was, and the Star-ratings step-down adds a 2028 item to the funding watch list. The quality caveat on reserve development also persists, though it applies more to the quarter than to the year.

Action: Upgrade to Outperform from Hold. The July downgrade was a call on price, and we said what price change would bring us back. The stock has since de-rated by about two turns on a base that management has raised again and extended into 2027, so the risk/reward has turned favorable without any heroic assumptions: ~20x a 2027 estimate that sits at the low end of management's own range. We hold conviction at 6 because the beat leaned on reserve development, revenue is not yet growing, and the DOJ exposure is still unknowable. We would step back to Hold on a 2027 outlook below the pointer, a re-acceleration in commercial trend, or a material DOJ quantification.